New drug combo aims to boost platelets in Hard-to-Treat ITP
NCT ID NCT07362199
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining rituximab with daratumumab can raise platelet counts in adults with immune thrombocytopenia (ITP) who have not responded to steroids. Twenty participants will receive one dose of rituximab and eight doses of daratumumab over eight weeks. The main goal is to see how many achieve a partial or complete response by week 12.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rituximab combined with daratumumab (anti-CD38 monoclonal antibody)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with immune thrombocytopenia who have not responded to steroids.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The combination may cause side effects or fail to improve platelet counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese Academy of Medical Science and Blood Disease Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug calm the immune System's attack on blood cells?
- Sleep hormone melatonin put to the test against lupus fatigue and inflammation
- Experimental injection aims to boost platelets in chronic blood disorder
- Can early jaw treatment in children prevent major surgery later?
- New combo therapy aims to boost platelets in immune disorder
- Brain training may help prevent alcohol relapse after withdrawal